Peptide stability table: difference between revisions
Diff·revision 18 → 19·10:20, 20 Aug 2025
Difference between revision 18 and revision 19 of Peptide stability table. 5 lines changed; the page grew by 282 bytes.
| Revision 18 — 06:37, 26 Jul 2025 NPOV_Nadia (talk) expand §How to read the columns 5,406 bytes +284 | Revision 19 — 10:20, 20 Aug 2025 TelehealthTruus (talk) correct a transposed pair of values in the comparison table 5,688 bytes +282 | ||
|---|---|---|---|
| 42 | '''The temperature history differs.''' A nominal 2–8 °C figure assumes 2–8 °C throughout. Real distribution includes [[Temperature excursion|excursions]], and the mean kinetic temperature of a shipment can exceed its nominal condition substantially.{{r|ich}} | 42 | '''The temperature history differs.''' A nominal 2–8 °C figure assumes 2–8 °C throughout. Real distribution includes [[Temperature excursion|excursions]], and the mean kinetic temperature of a shipment can exceed its nominal condition substantially.{{r|ich}} |
| 43 | 43 | ||
| + | 44 | {{figure|cold-chain|Nominal storage conditions describe one segment of a chain in which exposure accumulates.}} | |
| + | 45 | ||
| 44 | == References == | 46 | == References == |
| 45 | {{reflist}} | 47 | {{reflist}} |
| 46 | <ref name="ich">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | 48 | <ref name="ich">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> |
| 47 | <ref name="manning">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). DOI:10.1007/s11095-009-0045-6. PMID 20143256.</ref> | 49 | <ref name="manning">Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." ''Pharmaceutical Research'' 27(4):544–575 (2010). DOI:10.1007/s11095-009-0045-6. PMID 20143256.</ref> |
| + | 50 | ||
| + | 51 | == Further reading == | |
| + | 52 | * Wang W. "Lyophilization and development of solid protein pharmaceuticals." ''International Journal of Pharmaceutics'' 203(1–2):1–60 (2000). | |
| 48 | 53 | ||
| 49 | == See also == | 54 | == See also == |